Real-World Use of Psychedelics for OCD May Hold Promise, but Raises Concerns

Strategic Insights -

Researchers at the Baylor College of Medicine have presented new data on the potential benefits and risks of using psychedelics for Obsessive-Compulsive Disorder (OCD) in Hispanic and Latin American populations. The study, conducted as part of the Latin American Trans-ancestry Initiative for OCD genomics (LATINO) Study, found that 9% of respondents reported using psychedelics or related substances for treatment, with psilocybin, LSD, and MDMA being the most commonly used. The study's findings suggest that psychedelic users were more likely to be male, have received non-ERP therapy for OCD, and have a comorbid psychiatric diagnosis.

Key Takeaways:

  • A total of 2,639 adults participated in the study, which was conducted across 11 countries in the Americas.
  • 9% of respondents reported using psychedelics or related substances for treatment, with psilocybin, LSD, and MDMA being the most commonly used.
  • Psychedelic users compared to non-users were more likely to be male, have received non-ERP therapy for OCD, and have a comorbid psychiatric diagnosis.
  • Outcomes of psychedelic use for OCD-related symptoms varied widely by drug and were difficult to predict but were reported as most favorable for 'classic' serotonergic psychedelics.
  • The study's findings suggest that further research is needed to establish the conditions for safe and effective use of psychedelics in treating OCD in Hispanic and Latin American populations.

Statistics:

  • 2,639 adults participated in the study.
  • 9% of respondents reported using psychedelics or related substances for treatment.
  • Psilocybin, LSD, and MDMA were the most commonly used psychedelics.
  • 72% of respondents had received traditionally available treatments for OCD, such as psychiatric medication and/or psychotherapy.

Sources:

  • Brazilian Journal of Psychiatry, 2025.
  • NewsRx, October 18, 2025.
  • Assoc Brasileira Psiquiatria, Subscription Department, Rua Pedro De Toledo, 967 - Casa 01, Sao Paulo, Sp 04039-032 A, Brazil.
  • Jill O. Robinson, Ethical Legal Implications of Psychedelics in Society Program, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, United States.
  • David S. Mathai, Kevin Wagner, Logan Neitzke-Spruill, Dayan Berrones, Jacey L. Anderberg, Renee M. Frederick, Vanessa Zavala Cruz, Josselyn S. Munoz, Carolyn I. Rodriguez, Lynnette A. Averill, James J. Crowley, Eric A. Storch, and Amy L. Mc.